“Someone’s sitting in the shade today because someone planted a tree a long time ago.”
— Warren Buffett
Edwards Lifesciences Corp (NYSE: EW) stands out as a powerful example of long-term equity compounding. Over the 20-year period beginning in August 2006, EW delivered a return that far exceeded the original capital invested, driven by sustained share-price appreciation rather than dividend income. For investors studying long-duration wealth creation, the stock’s history offers a clear illustration of how a strong operating business can translate into exceptional shareholder returns over time.
The central result is straightforward: a $10,000 investment in EW on 08/28/2006 would have grown to $235,745.50 by 08/26/2026, assuming no sale during the period. That equates to a total return of 2,257.92% and an average annual return of 17.11%. Because Edwards Lifesciences did not contribute to this result through dividend reinvestment, the outcome reflects capital appreciation almost entirely.
EW 20-Year Return at a Glance
| Start date: | 08/28/2006 |
|
|||
| End date: | 08/26/2026 | ||||
| Start price/share: | $3.85 | ||||
| End price/share: | $90.78 | ||||
| Starting shares: | 2,597.40 | ||||
| Ending shares: | 2,597.40 | ||||
| Dividends reinvested/share: | $0.00 | ||||
| Total return: | 2,257.92% | ||||
| Average annual return: | 17.11% | ||||
| Starting investment: | $10,000.00 | ||||
| Ending investment: | $235,745.50 | ||||
What Drove the Long-Term Return?
The return profile is notable for one reason in particular: it was achieved without dividend support. Many 20-year success stories rely on a combination of income and reinvestment. EW’s case is different. The ending share count is unchanged, and dividends reinvested per share are listed at $0.00, meaning the gain came from the market assigning a much higher value to the business over time.
That distinction matters. When a stock compounds primarily through price appreciation, the market is usually responding to a durable expansion in earnings power, competitive position, or both. Edwards Lifesciences is widely associated with structural growth in heart valve therapies and related medical technologies, and the long-term stock performance is consistent with a company that successfully converted clinical demand and product leadership into shareholder value.
Key Takeaways From EW’s 20-Year Performance
1. Compounding becomes most visible over long periods.
The move from $10,000 to $235,745.50 did not require leverage or dividend reinvestment. Time and sustained business execution did the heavy lifting.
2. Annualized returns tell the real story.
A 2,257.92% total return is striking, but the 17.11% annualized return is the more useful figure for comparison across investments and time periods.
3. Share-price volatility and business value are not the same thing.
Over any two-decade stretch, even strong stocks typically experience corrections, drawdowns, and sentiment reversals. The long-term outcome depends more on fundamental progress than on short-term trading noise.
4. Dividend absence does not preclude strong total returns.
EW demonstrates that non-dividend-paying or low-yield equities can still create substantial wealth when earnings growth and valuation expansion are sustained.
How to Interpret a 17.11% Annual Return
An average annual return of 17.11% over 20 years is exceptional. Small differences in annualized performance create enormous differences in ending wealth when compounded across decades. That is why long-horizon return analysis is more informative than focusing only on a stock’s recent one-year or even five-year move.
It is also worth distinguishing between a strong historical result and the assumptions needed to repeat it. A stock that delivered outsized returns over the last two decades may now face a different valuation backdrop, competitive landscape, or growth trajectory. Historical compounding can reveal what the business achieved, but it does not by itself establish what returns will look like from today’s starting point.
A Simple Answer to the Core Question
How did an investment in Edwards Lifesciences perform over the last 20 years?
A $10,000 investment in EW on 08/28/2006 grew to $235,745.50 by 08/26/2026. That represents a 2,257.92% total return and a 17.11% annualized return, with no contribution from dividend reinvestment.
The figures above were computed with the Dividend Channel DRIP Returns Calculator.
“Investors should always keep in mind that the most important metric is not the returns achieved but the returns weighed against the risks incurred. Ultimately, nothing should be more important to investors than the ability to sleep soundly at night.” — Seth Klarman
